Phaseline

Targets › TRIM5

TRIM5 (Tripartite motif-containing protein 5): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2036.

Capsid-specific restriction factor that prevents infection from non-host-adapted retroviruses. Blocks viral replication early in the life cycle, after viral entry but before reverse transcription. (UniProt, Q9C035)

Open in Phaseline: the race on TRIM5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AIDS Malignancy ConsortiumLentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-pos
Gene therapy using lentiviral vector expressing CCR5 shRNA, TRIM5alpha, and TAR decoy in a
CCR5, TRIM5Phase 1HIV InfectionMar 2036

Conditions

HIV Infection (1)

Modalities

mixed (1)

Companies

AIDS Malignancy Consortium (1)

Related targets

CCR5 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.